Rapid increase in multidrug-resistant enteric bacilli blood stream infection after prostate biopsy-A 10-year population-based cohort study

Aly, Markus; Dyrdak, Robert; Nordström, Tobias; Jalal, Shah; Weibull, Caroline E.; Giske, Christian G.; Grönberg, Henrik

doi:10.1002/pros.22979

Cited by 38 publications

(28 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Biomarker analysis typically requires tissue biopsy, which is invasive, may involve inadequate sampling of heterogeneous tumors, and can be associated with patient discomfort and risk for complications (3)(4)(5)(6)(7)(8). Tissue biopsy is also not routinely feasible for longitudinal measurement of biomarkers in patients undergoing treatment.…”

Section: Implications For Patient Carementioning

confidence: 99%

Release of Cell-free MicroRNA Tumor Biomarkers into the Blood Circulation with Pulsed Focused Ultrasound: A Noninvasive, Anatomically Localized, Molecular Liquid Biopsy

et al. 2017

View full text Add to dashboard Cite

Section: Implications For Patient Carementioning

confidence: 99%

Release of Cell-free MicroRNA Tumor Biomarkers into the Blood Circulation with Pulsed Focused Ultrasound: A Noninvasive, Anatomically Localized, Molecular Liquid Biopsy

et al. 2017

View full text Add to dashboard Cite

“…However, although very high PSA values indicate a high probability of cancer detection by biopsy, lower values poorly discriminate PCa from inflammatory processes and benign hyperplasia ( Ploussard et al , 2013 ; Hayes and Barry, 2014 ). On the basis of the results of two large epidemiological studies showing a very small or no effect of PSA testing on PCa mortality ( Andriole et al , 2012 ; Schroder et al , 2012 ) and the negative consequences of PSA screening, which include overdiagnosis, overtreatment and treatment complications, the US Preventive Services Task Force recommended against the use of PSA testing for PCa screening ( Aly et al , 2015 ; Johnson et al , 2015 ).…”

mentioning

confidence: 99%

A circulating miRNA assay as a first-line test for prostate cancer screening

et al. 2016

View full text Add to dashboard Cite

Background:Prostate cancer (PCa) screening currently relies on prostate-specific antigen (PSA) testing and digital rectal examination. However, recent large-scale studies have questioned the long-term efficacy of these tests, and biomarkers that accurately identify PCa are needed.Methods:We analysed the levels of circulating microRNAs (miRNAs) in patients with elevated PSA who were diagnosed with either localised PCa (n=36) or benign prostatic hyperplasia (BPH, n=31) upon biopsy. Real-time RT–PCR with Taqman probes was used to measure plasma levels of miRNAs. To circumvent problems associated with circulating miRNA quantitation, we computed the expression ratios of upregulated and downregulated miRNAs.Results:The miR-106a/miR-130b and miR-106a/miR-223 ratios were significantly different between the biopsy-positive and BPH groups (P<0.0001), and yielded statistical power values that were >0.99. Both miRNA ratios were highly sensitive and more specific than PSA in discriminating localised PCa from BPH. Receiver operating characteristic curve analysis revealed area under curve values of 0.81 (miR-106a/miR-130b) and 0.77 (miR-106a/miR-223).Conclusions:Testing for circulating miR-106a/miR-130b and miR-106a/miR-223 ratios may reduce the costs and morbidity of unnecessary biopsies and is feasible for large-scale screening, as it requires measuring only three miRNAs.

show abstract

“…The number of cases increased from two to 18, before and after the year 2010, respectively. 65 A prospective multicenter study conducted in Turkey showed that 19% of 400 men undergoing PNB carried ESBL-producing organisms. 66 Presence was significantly associated with concurrent diabetes and previous fluoroquinolone usage ( P <0.05).…”

Section: Special Considerationsmentioning

confidence: 99%

Strategies for prevention of ultrasound-guided prostate biopsy infections

Raman

2016

IDR

View full text Add to dashboard Cite

Prostate cancer is the most common cancer in male patients and the second leading cause of cancer-related mortality in males. To confirm the diagnosis of prostate cancer, an ultrasound-guided needle biopsy is necessary to obtain prostate tissue sufficient for histologic analysis by pathologists. Ultrasound-guided prostate needle biopsy can be accomplished via a transperineal or transrectal approach. The latter biopsy technique involves placing an ultrasound probe into the rectum, visualizing the prostate located just anterior to it, and then obtaining 12–14 biopsies. Each biopsy core requires piercing of the rectal mucosa which can inherently contribute to infection. The increasing infectious risk of prostate needle biopsy requires refinement and re-evaluation of the process in which the technique is performed. Such processes include (but are not limited to) prebiopsy risk stratification, antibiotic prophylaxis, use of rectal preparations, and equipment processing. In the subsequent review, we highlight the current available information on different strategies to reduce the risk of infection following prostate needle biopsy.

show abstract

Rapid increase in multidrug-resistant enteric bacilli blood stream infection after prostate biopsy-A 10-year population-based cohort study

Cited by 38 publications

References 20 publications

Release of Cell-free MicroRNA Tumor Biomarkers into the Blood Circulation with Pulsed Focused Ultrasound: A Noninvasive, Anatomically Localized, Molecular Liquid Biopsy

Release of Cell-free MicroRNA Tumor Biomarkers into the Blood Circulation with Pulsed Focused Ultrasound: A Noninvasive, Anatomically Localized, Molecular Liquid Biopsy

A circulating miRNA assay as a first-line test for prostate cancer screening

Strategies for prevention of ultrasound-guided prostate biopsy infections

Contact Info

Product

Resources

About